PRCT (PROCEPT BioRobotics Corporation) Stock Financials & Earnings | Market Cap Arena

PRCT (PROCEPT BioRobotics Corporation) Stock Financials & Earnings | Market Cap Arena

PRCTPROCEPT BioRobotics Corporation

Mkt Cap$1B

Healthcare·Medical - Devices·🇺🇸 United States·NASDAQ

Revenue (TTM)$308M

Net Income (TTM)-$96M

EPS (TTM)-$1.72

Free Cash Flow (TTM)-$58M

Gross Margin63.7%

Op. Margin-33.7%

Net Margin-31.0%

FCF Margin-18.9%

P/S Ratio (TTM)4.6x

P/E Ratio (TTM)—

YoY Rev Growth+37.2%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$24M	$12M	-$28M
Q2 23	$33M	$18M	-$26M
Q3 23	$35M	$19M	-$26M
Q4 23	$44M	$21M	-$30M
Q1 24	$45M	$25M	-$28M
Q2 24	$53M	$31M	-$27M
Q3 24	$58M	$37M	-$22M
Q4 24	$68M	$44M	-$20M
Q1 25	$69M	$44M	-$27M
Q2 25	$79M	$52M	-$22M
Q3 25	$83M	$54M	-$23M
Q4 25	$76M	$46M	-$31M

Valuation

Quarter	P/S	P/E
Q1 23	16.7x	—
Q2 23	14.0x	—
Q3 23	12.3x	—
Q4 23	10.5x	—
Q1 24	9.1x	—
Q2 24	8.1x	—
Q3 24	7.1x	—
Q4 24	6.4x	—
Q1 25	5.7x	—
Q2 25	5.2x	—
Q3 25	4.8x	—
Q4 25	4.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$36M	-$41M
Q2 23	-$28M	-$34M
Q3 23	-$19M	-$25M
Q4 23	-$25M	-$34M
Q1 24	-$32M	-$34M
Q2 24	-$16M	-$17M
Q3 24	-$19M	-$19M
Q4 24	-$32M	-$34M
Q1 25	-$17M	-$19M
Q2 25	-$15M	-$18M
Q3 25	-$7M	-$10M
Q4 25	-$10M	-$12M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$5M
Q2 23	$5M
Q3 23	$6M
Q4 23	$9M
Q1 24	$2M
Q2 24	$1M
Q3 24	$246K
Q4 24	$1M
Q1 25	$2M
Q2 25	$3M
Q3 25	$3M
Q4 25	$2M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+71.9%	+76.5%
Q2 23	+98.3%	+69.9%
Q3 23	+72.5%	+43.0%
Q4 23	+83.3%	+49.8%
Q1 24	+82.5%	+36.8%
Q2 24	+61.2%	+36.5%
Q3 24	+66.3%	+33.1%
Q4 24	+56.6%	+20.2%
Q1 25	+55.3%	+33.8%
Q2 25	+48.4%	+26.4%
Q3 25	+42.8%	+31.8%
Q4 25	+11.9%	+22.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$4M	15.3%
Q2 23	$5M	15.4%
Q3 23	$5M	15.2%
Q4 23	$5M	11.4%
Q1 24	$6M	14.0%
Q2 24	$8M	15.0%
Q3 24	$9M	14.6%
Q4 24	$9M	13.3%
Q1 25	$10M	14.6%
Q2 25	$12M	15.4%
Q3 25	$14M	17.4%
Q4 25	$11M	14.2%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$11M	$30M
Q2 23	$12M	$32M
Q3 23	$12M	$33M
Q4 23	$14M	$36M
Q1 24	$13M	$40M
Q2 24	$18M	$41M
Q3 24	$17M	$43M
Q4 24	$15M	$48M
Q1 25	$16M	$55M
Q2 25	$18M	$56M
Q3 25	$18M	$59M
Q4 25	$19M	$58M

Revenue by Geography

Quarter	Outside the United States	United States
Q3 23	$3M	$32M
Q1 24	$4M	$40M
Q2 24	$6M	$48M
Q3 24	$6M	$52M
Q4 24	$8M	$60M
Q1 25	$9M	$60M
Q2 25	$10M	$70M
Q3 25	$9M	$74M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$182M	$0	$182M
Q2 23	$150M	$0	$150M
Q3 23	$288M	$0	$288M
Q4 23	$257M	$0	$257M
Q1 24	$226M	$0	$226M
Q2 24	$214M	$0	$214M
Q3 24	$197M	$0	$197M
Q4 24	$334M	$0	$334M
Q1 25	$316M	$0	$316M
Q2 25	$303M	$0	$303M
Q3 25	$294M	$0	$294M
Q4 25	$287M	$0	$287M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	45M	+0.7%
Q2 23	45M	+0.2%
Q3 23	48M	+7.0%
Q4 23	51M	+4.7%
Q1 24	51M	+0.8%
Q2 24	52M	+1.2%
Q3 24	52M	+0.8%
Q4 24	54M	+3.5%
Q1 25	55M	+2.0%
Q2 25	55M	+1.0%
Q3 25	56M	+0.5%
Q4 25	56M	+0.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 19	—	—
FY 20	—	—
FY 21	$3M	13
FY 22	$175K	428
FY 23	$218K	626
FY 24	$297K	756
FY 25	$347K	888